Protagenic Therapeutics (PTIX) exec chair purchases 5,000 shares at $0.2588
Rhea-AI Filing Summary
Protagenic Therapeutics, Inc. director and executive chair Armen Garo H purchased 5,000 shares of common stock on August 5, 2026 at $0.2588 per share in an open-market or private transaction. Following this buy, he directly holds 31,294 common shares. The transaction was not reported as made under a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 5,000 shares
Net Buy
1 txn
Insider
ARMEN GARO H
Role
EXEC. CHAIR & PRINCIPAL OFF
Bought
5,000 shs ($1K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | COMMON STOCK | 5,000 | $0.2588 | $1K |
Holdings After Transaction:
COMMON STOCK — 31,294 shares (Direct)
Key Figures
Shares purchased: 5,000 shares of common stock
Purchase price: $0.2588 per share
Shares owned after transaction: 31,294 shares
+1 more
4 metrics
Shares purchased
5,000 shares of common stock
Non-derivative purchase on August 5, 2026
Purchase price
$0.2588 per share
Price paid for the 5,000-share common stock purchase
Shares owned after transaction
31,294 shares
Direct common stock holdings following the reported trade
Net buy shares
5,000 shares
Net effect of reported transactions in this Form 4
Key Terms
non-derivative, open market or private transaction, direct ownership
3 terms
non-derivative financial
"The transaction is classified as a non-derivative purchase of common stock"
open market or private transaction financial
"Transaction code description: Purchase in open market or private transaction"
direct ownership financial
"The ownership type for these shares is recorded as direct ownership"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did PTIX report for Armen Garo H?
Protagenic Therapeutics (PTIX) reported that executive chair and director Armen Garo H purchased 5,000 common shares on August 5, 2026. The buy was recorded as a non-derivative, open-market or private transaction at a specified per-share price.
Was the PTIX insider trade made under a Rule 10b5-1 trading plan?
The filing indicates the transaction was not affirmatively reported as made under a Rule 10b5-1 trading plan. The document-level Rule 10b5-1 checkbox is unchecked, suggesting the purchase was not executed under such a pre-arranged plan.
What role does the PTIX insider involved in this Form 4 hold?
The reporting person, Armen Garo H, is listed as both a director and an officer of Protagenic Therapeutics (PTIX), with the officer title “EXEC. CHAIR & PRINCIPAL OFF,” indicating a senior leadership and governance position.
Is the reported PTIX insider ownership direct or indirect?
The Form 4 classifies Armen Garo H’s post-transaction holding of 31,294 shares as direct ownership. The ownership type is coded as direct, meaning the shares are held in his own name rather than through an intermediary entity.